MARC details
| 000 -LEADER |
|---|
| fixed length control field |
03806nam a22003497a 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
170823s20122012 xxu||||| |||| 00| 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER |
|---|
| International Standard Serial Number |
0732-183X |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
Ovid MEDLINE(R) |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) |
|---|
| PMID |
28140798 |
| 245 ## - TITLE STATEMENT |
|---|
| Title |
NSABP B-38: Definitive analysis of a randomized adjuvant trial comparing dose-dense (DD) AC->paclitaxel (P) plus gemcitabine (G) with DD AC->P and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-positive breast cancer. |
| 251 ## - Source |
|---|
| Source |
Journal of Clinical Oncology. 30(18_suppl):LBA1000, 2012 Jun 20 |
| 252 ## - Abbreviated Source |
|---|
| Abbreviated source |
J Clin Oncol. 30(18_suppl):LBA1000, 2012 Jun 20 |
| 253 ## - Journal Name |
|---|
| Journal name |
Journal of clinical oncology : official journal of the American Society of Clinical Oncology |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Year |
2012 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Manufacturer |
FY2012 |
| 266 ## - Date added to catalog |
|---|
| Date added to catalog |
2017-08-23 |
| 501 ## - WITH NOTE |
|---|
| Local holdings |
Available online from MWHC library: 1999 - present, Available in print through MWHC library: 1999 - 2008 |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
AML/MDS: N=5, 8, 11. All cycles completed in 91% for TAC and 88% for DD regimens. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
CONCLUSIONS: Addition of G to DD AC->P did not improve outcomes. No significant differences in efficacy endpoints were identified between DD AC->P and TAC, though toxicity profiles differed. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
FUNDING: NCI PHS U10-CA-37377, -69974, -12027, -69651 and NCCTG U10-CA25224, with additional funding from Eli Lilly & Company, and Amgen, Inc. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
LBA1000 Background: The primary aims were to determine whether adjuvant DD AC->PG will be superior to DD AC->P as well as to TAC in DFS and to compare the relative DFS of TAC and DD AC->P. Secondary endpoints include survival and toxicity. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
METHODS: From Nov 3, 2004 to May 3, 2007, 4894 women were randomized; 1630 to TAC (docetaxel [T] 75 mg/m<sup>2</sup>, doxorubicin [A] 50 mg/m<sup>2</sup>, cyclophosphamide [C] 500 mg/m<sup>2</sup> q3 wks x 6), 1634 to DD AC->P (A 60 mg/m<sup>2</sup> and C 600 mg/m<sup>2</sup> q2 wks x 4 followed by P 175 mg/m<sup>2</sup> q2 wks x 4), and 1630 to DD AC->PG (A 60 mg/m<sup>2</sup> and C 600 mg/m<sup>2</sup> q2 wks x 4 -> P 175 mg/m<sup>2</sup> + G 2000 mg/m<sup>2</sup>q2 wks x 4). Primary G-CSF support was required and erythropoiesis-stimulating agents (ESA) were used at investigator discretion. 52% were postmenopausal, 65% had 1 - 3 positive nodes, and 80% had HR+ breast cancer. Log-rank tests were used for pair-wise comparisons of the primary (DFS) and secondary (OS) endpoints among the three treatment arms. |
| 520 ## - SUMMARY, ETC. |
|---|
| Abstract |
RESULTS: With 64 months median follow-up, 5-year DFS in DD AC->PG group was 80.6% compared with 82.2% in DD AC->P group (HR=1.1; p=0.27) and 80.1 % (HR=0.97; p=0.71) in TAC group. 5-year OS was 90.8% in DD AC->PG group as compared with 89.1% (HR=.89; p=0.25) in DD AC->P group and 89.6 % (HR=0.90; p=0.32) in TAC group. HR for DFS and OS of DD AC->P vs. TAC were 0.89 (p=0.14) and 1.01 (p=0.92) respectively. Toxicities for TAC, DD AC->P, DD AC->PG, respectively: febrile neutropenia (Gr 3/4: 9%, 4%, 4% [p<0.001]), sensory neuropathy (Gr 3/4: <1%, 7%, 6% [p<0.001]), diarrhea (Gr 3/4: 8 %, 2%, 2% [p<0.001]). Hgb was <10 in 12%, 26%, 33% with ESA use in 35.2%, 47%, 51.6% and transfusions in 3.7%, 6.3%, 9.4%. Deaths on treatment: N=13, 5, 7 (p=0.2). |
| 546 ## - LANGUAGE NOTE |
|---|
| Language note |
English |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
IN PROCESS -- NOT YET INDEXED |
| 651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME |
|---|
| Institution |
Medstar Franklin Square Medical Center |
| 657 ## - INDEX TERM--FUNCTION |
|---|
| Medline publication type |
Journal Article |
| 700 ## - ADDED ENTRY--PERSONAL NAME |
|---|
| Local Authors |
Zapas, John L |
| 790 ## - Authors |
|---|
| All authors |
Atkins JN, Azar CA, Biggs DD, Brufsky A, Costantino JP, Donnellan PP, Fehrenbacher L, Geyer CE, Levine EA, Mamounas EP, Paik S, Perez EA, Polikoff J, Provencher L, Rastogi P, Robidoux A, Tang G, Wolmark N, Zapas JL |
| 856 ## - ELECTRONIC LOCATION AND ACCESS |
|---|
| DOI |
<a href="https://dx.doi.org/10.1200/jco.2012.30.18_suppl.lba1000">https://dx.doi.org/10.1200/jco.2012.30.18_suppl.lba1000</a> |
| Public note |
https://dx.doi.org/10.1200/jco.2012.30.18_suppl.lba1000 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Koha item type |
Journal Article |
| Item type description |
Article |
